Scottish startup Nami Surgical bags €3.7M funding to advance robotic surgery

Glasgow-based Nami Surgical, a spin-out company from the Centre for Medical and Industrial Ultrasonics (C-MIU) at the University of Glasgow, announced on Wednesday, May 8, that it has secured $4M (approximately €3.7M) of investment and grant funding. 

Eos Advisory, an impact investment firm based in St Andrews, led the seed round with $3.1M approximately €2.8M). 

The Investment Fund for Scotland, managed by UK private equity firm Maven and delivered by British Business Bank, Scottish Enterprise, and SIS Ventures, also participated in the round. 

What does Nami Surgical solve?

Additionally, the company was awarded a grant from Innovate UK, the United Kingdom’s national innovation agency.

Robotic surgeries are known for their ability to enhance surgical precision and dexterity, which results in reduced patient trauma, less post-operative pain, and faster recovery times. 

This leads to shorter hospital stays and increased patient satisfaction. 

As robotic surgery becomes the norm for various procedures, the global market for it is expected to quadruple, reaching approximately $36B (approximately €33B)  by 2032. 

Here’s where Nami’s technology, the integration of ultrasonic scalpels in robotic surgeries comes into play!

Nami Surgical: Unlocking the future of ultrasonic surgery

Founded by Nico Fenu and Dr. Rebecca Cleary in 2022, Nami Surgical develops miniaturised ultrasonic medical devices for surgical applications and supports medical device companies to deliver innovation in ultrasonic surgery. 

The Scottish company has introduced a high-performance, miniaturised ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery. 

Traditionally favoured in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.

Nami Surgical’s CEO and Co-founder Nico Fenu say, “Robot-assisted surgery has become increasingly popular in recent years and is now widely used in various surgical procedures, including urology, gynaecology, and colorectal. We have pilot programmes running with healthcare and medical device groups worldwide, including in the United States, and we now look forward to the commercialisation phase with the support of our new investors.”

Nico Fenu adds, “We are committed to close collaboration with clinicians and companies in the industry to translate their needs into novel devices that not only improve patient outcomes but also drive ultrasonic surgery to the next level. It’s an exciting time for us, and we are just getting started.”